VIRGINIA RETIREMENT SYSTEMS ET Al Buys 32,700 Shares of Arcutis Biotherapeutics, Inc. $ARQT

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 32,700 shares of the company’s stock, valued at approximately $864,000.

Several other institutional investors and hedge funds also recently bought and sold shares of ARQT. Pinnacle Wealth Planning Services Inc. acquired a new position in Arcutis Biotherapeutics in the 3rd quarter valued at approximately $36,000. Nykredit A S acquired a new stake in Arcutis Biotherapeutics during the second quarter valued at $63,000. Integrated Wealth Concepts LLC acquired a new stake in Arcutis Biotherapeutics during the second quarter valued at $84,000. Sterling Capital Management LLC increased its position in Arcutis Biotherapeutics by 839.3% in the 3rd quarter. Sterling Capital Management LLC now owns 3,776 shares of the company’s stock worth $100,000 after purchasing an additional 3,374 shares during the last quarter. Finally, KBC Group NV raised its stake in shares of Arcutis Biotherapeutics by 43.2% during the 1st quarter. KBC Group NV now owns 4,376 shares of the company’s stock worth $103,000 after purchasing an additional 1,321 shares in the last quarter.

Arcutis Biotherapeutics News Summary

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Arcutis began enrolling participants in a Phase 3 trial of ZORYVE cream 0.3% for moderate-to-severe atopic dermatitis. Success could expand the treatment’s use and address a broader patient population, though the study is an early-stage catalyst rather than near-term revenue. Phase 3 study announcement
• Positive Sentiment: Third-quarter revenue was $143.92 million, modestly ahead of the approximately $142.6 million analyst consensus, providing a partial offset to the earnings miss. Quarterly earnings report
• Neutral Sentiment: Rob Lisicki was appointed chief commercial officer, effective November 4. The leadership change may support commercial execution, but its impact on sales remains to be seen. Chief commercial officer appointment
• Neutral Sentiment: Several executives reported share sales, including a larger sale by EVP Masaru Matsuda under a pre-arranged trading plan. Some reported transactions were to cover tax withholding on vested equity awards, which makes them less clearly bearish, though insider selling may attract investor attention. SEC insider filing
• Negative Sentiment: Third-quarter earnings were $0.06 per share, well below analysts’ estimates of roughly $0.17–$0.18 and unchanged from a year earlier. The earnings miss was the clearest near-term pressure on the stock, despite the modest revenue beat. Report on the earnings miss

Analyst Ratings Changes

A number of analysts have issued reports on the stock. Guggenheim lifted their target price on shares of Arcutis Biotherapeutics from $38.00 to $44.00 and gave the company a “buy” rating in a research note on Monday, October 19th. Needham & Company LLC set a $40.00 price target on Arcutis Biotherapeutics in a research report on Thursday. Morgan Stanley increased their price objective on Arcutis Biotherapeutics from $34.00 to $38.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Jefferies Financial Group restated a “buy” rating and issued a $39.00 price objective on shares of Arcutis Biotherapeutics in a research note on Thursday, October 8th. Finally, Cantor Fitzgerald began coverage on shares of Arcutis Biotherapeutics in a research report on Thursday, October 15th. They set an “overweight” rating and a $48.00 target price for the company. Eight investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $39.75.

Insider Activity at Arcutis Biotherapeutics

In other news, insider Todd Watanabe sold 4,377 shares of the company’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $31.86, for a total value of $139,451.22. Following the sale, the insider owned 712,826 shares of the company’s stock, valued at approximately $22,710,636.36. This represents a 0.61% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Patrick Burnett sold 943 shares of Arcutis Biotherapeutics stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $31.86, for a total transaction of $30,043.98. Following the completion of the transaction, the executive vice president owned 116,649 shares of the company’s stock, valued at $3,716,437.14. This trade represents a 0.80% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 123,932 shares of company stock valued at $3,553,077. Corporate insiders own 9.40% of the company’s stock.

Arcutis Biotherapeutics Stock Down 20.7%

ARQT stock opened at $27.00 on Friday. Arcutis Biotherapeutics, Inc. has a twelve month low of $19.30 and a twelve month high of $34.80. The company has a market cap of $3.39 billion, a PE ratio of 128.58 and a beta of 1.66. The business’s 50-day simple moving average is $27.15 and its 200 day simple moving average is $25.37. The company has a quick ratio of 2.67, a current ratio of 2.92 and a debt-to-equity ratio of 0.46.

Arcutis Biotherapeutics (NASDAQ:ARQT) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.12). The firm had revenue of $143.92 million during the quarter, compared to the consensus estimate of $142.59 million. Arcutis Biotherapeutics had a return on equity of 14.96% and a net margin of 5.88%. On average, research analysts anticipate that Arcutis Biotherapeutics, Inc. will post 0.43 earnings per share for the current year.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for dermatologic conditions. The company’s portfolio is centered on therapies designed to address inflammatory skin diseases, with an emphasis on nonsteroidal topical medicines that may help patients manage chronic conditions.

Arcutis’s lead product is ZORYVE (roflumilast), a topical phosphodiesterase-4 inhibitor. ZORYVE has received U.S. Food and Drug Administration approvals for multiple dermatological uses, including plaque psoriasis, seborrheic dermatitis and atopic dermatitis, in different cream and foam formulations.